EP1805205A1 - Verfahren zur rückfaltung von polypeptiden - Google Patents

Verfahren zur rückfaltung von polypeptiden

Info

Publication number
EP1805205A1
EP1805205A1 EP05851250A EP05851250A EP1805205A1 EP 1805205 A1 EP1805205 A1 EP 1805205A1 EP 05851250 A EP05851250 A EP 05851250A EP 05851250 A EP05851250 A EP 05851250A EP 1805205 A1 EP1805205 A1 EP 1805205A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
protein
polypeptides
methods
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05851250A
Other languages
English (en)
French (fr)
Inventor
Joe X. Zhou
Tony Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/255,528 external-priority patent/US7928205B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP1805205A1 publication Critical patent/EP1805205A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • Polypeptides, and in particular antibodies can be post- translationally modified in undesired ways leading to heterogeneity in structure, which can correspondingly lead to a reduction in function.
  • Some of these modifications include incomplete galactosylation and fucosylation of the two N- linked biantennary oligosaccharides attached to the second constant domain (CH2) of the heavy chain, N-terminal glutamine residue of the heavy chain conversion posttranslationally to pyroglutamate, C-terminal lysine modification, in addition to the following modifications: oxidation, deamidation, isomerization of aspartic acid, disulfide bond scrambling, cleavages, dimer formation, and others (Dillon et al., Journal of Chromatography A, 1053 (2004) 299-305 and references cited therein).
  • One way of improving the yield of a correctly and homogeneously folded, biologically active polypeptide is to improve the purification processes used to isolate the polypeptide, whether it has been expressed in a prokaryotic or a eukaryotic system.
  • Prior methods have been provided for obtaining a correctly folded population of fusion polypeptides, e.g., Sassenfeld et al., WO 02/068455.
  • the present inventors have developed a method that results in improved efficiency of obtaining a desired conformation of a polypeptide that is captured on a column, during a commercial scale up process.
  • the present invention is directed to providing efficient and economic production and purification of active polypeptides. More particularly, A-1056 - 3 - the invention describes methods to improve purification of a correctly folded and more active polypeptide by virtue of a refolding process.
  • redox reduction/oxidation
  • the addition of reduction/oxidation (redox) agents alone or in combination with mildly denaturing conditions, i.e., with a chaotropic agent, to a polypeptide that is captured on a column during a purification process can facilitate the folding of a population of polypeptides where disulphide bonds are more uniform and thus result in a greater percentage of structurally homogeneous and therefore active forms of the molecule.
  • one aspect of the invention is directed to methods of modifying an Fc domain containing polypeptide on a column comprising mixing a redox reagent alone or in combination and a mildly denaturing reagent with an Fc domain containing polypeptide that has been immobilized on a column.
  • the redox reagent with or without the denaturing agent, then promotes conformational changes of the Fc domain containing polypeptides to a more homogeneous structural conformation than would be present without the treatment.
  • the methods of the invention broadly comprise producing an Fc domain containing polypeptide, isolating the polypeptide on a column and contacting said polypeptide with a reduction/oxidation reagent at a pH of about 5 to about 11 ; and optionally further contacting said preparation with a chaotropic agent before, after or concurrently with said contacting with said reduction/oxidation reagent.
  • the methods further comprise eluting and isolating the treated polypeptide.
  • the redox reagent can be any suitable redox reagent, and in one embodiment comprises cysteine/cystine.
  • the concentration of the redox reagent can be up to 30 mM, and can be in a range of 30 mM to 1 mM, or 25 mM to 5 mM or 15 mM to 5 mM.
  • the ratio of cysteine to cystine can be 50 to 1, 40 to I 5 33 to 1, 25 to 1, 20 to 1, 17 to 1, 12 to 1 or 10 to 1 or even less depending on the reaction condition that best suits the Fc domain containing polypeptide.
  • the pH of the redox reagent can be from about 7 to about 10, or more specifically from about 7 to about 9. In one specific, non-limiting exemplary embodiment the pH of the redox reagent is about 8.
  • the method can be performed at a temperature of from about 5°C to about 40°C, and is more preferably at about 18°C to about 25°C ⁇ e.g. , at or near room temperature).
  • the methods of the present invention may further comprise an additional step of contacting the isolated polypeptide with a chaotropic agent.
  • the chaotropic agent can be selected from the group consisting of urea, SDS and guanidine hydrochloride.
  • the chaotropic agent is guanidine hydrochloride present in the reaction mixture in a final concentration of about 0.1 M to about 1.5 M.
  • the step of contacting with the redox reagent and/or a chaotropic agent with the Fc domain containing polypeptide on the column may be performed over a sufficient time period to allow the desired conformational changes to occur.
  • the contacting step with the redox agent, and/or the chaotropic agent is performed for about 1 to about 48 hours, hi other aspects, the incubation period is more than 2 hours and less than 24 hours, hi a certain embodiment, the incubation is about three to four hours.
  • Capturing the Fc domain containing polypeptide on a column may be done using conventionally methods.
  • This step may comprise prior steps to purify the polypeptide, such as one or more techniques selected from the group consisting of HPLC, size-exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, and capillary electrophoresis, followed by capture on a protein A, protein G or protein L column. While captured on a column, the concentration of the polypeptide for use in the methods of the invention may be any concentration that is amenable to refolding. In specific embodiments, the concentration of polypeptide in the reaction mixture is from about 1 g/L to about 50 g/L, from about 10 g/L to about 40 g/L, or from 20 g/L to about 30 g/L. A-1056 - 5 -
  • the methods of the invention are characterized in that the contacting with the redox reagent produces an increase in the biological activity of the polypeptide as compared to the same polypeptide that has not been prepared using the methods of the invention.
  • the relative concentration of the desired conformation of the polypeptide is increased compared to untreated polypeptide (enriched or increased abundance), thereby increasing the activity of the recovered polypeptide.
  • the methods of the invention produce a polypeptide population which may further be processed by formulating into a sterile bulk form. In other embodiments include formulating the polypeptide used in the methods of the invention into a sterile unit dose form.
  • Also encompassed by the present invention is a population of Fc domain containing polypeptides prepared according the method of any of claims described herein.
  • the present invention is directed to addressing a need for commercial scale methods of producing a homogeneous conformation population of polypeptides, and more particularly, homogenous mammalian-cell produced Fc domain containing polypeptides.
  • the present inventors have discovered that contacting an Fc domain containing polypeptide while it is captured on a purification column with redox agents, with or without a chaotropic agent, can facilitate the formation of correct disulphide bonds and structure of the polypeptide. These polypeptides have then been shown to have improved biological activity relative to untreated polypeptides.
  • the reduction/oxidation reagent is a source of reducing agents.
  • Preferred reducing agents are free thiols.
  • the reduction/oxidation reagent can be selected from the group consisting of cysteine and cystine, reduced and oxidized glutathione, dithiothreitol (DTT), 2-mercaptoethanol, hydrogen peroxide (oxidizer) and dithionitrobenzoate.
  • DTT dithiothreitol
  • 2-mercaptoethanol hydrogen peroxide
  • hydrogen peroxide oxidizer
  • dithionitrobenzoate dithionitrobenzoate.
  • reduced glutathione and/or reduced cysteine can be used.
  • the redox reagent may be added to the fermentation media in which the cells producing the polypeptide are grown.
  • the reagents also may be added to the liquid chromatography (LC) mobile phase during the LC separation step for separating the polypeptide.
  • LC liquid chromatography
  • the antibody isotype of IgG2 has shown using LC methods to elute as three major peaks from HPLC.
  • the use of the reduction/oxidation reagent and/or chaotropic agent while the polypeptide is on a column can promote conformational changes such that there is a more uniform, single peak. It is contemplated that this more uniform peak, i.e., as A-1056 - 7 - exemplified by peak 3 shown in the examples, may be isolated as a more homogeneous, and therefore more active, preparation of IgG2.
  • the reduction/oxidation reagent is present at a concentration sufficient to increase the relative proportion of the desired conformation.
  • the optimal concentration of the reduction/oxidation reagent depends upon the concentration of protein and number of disulfide bonds in the protein.
  • the concentration of free thiols from the reduction/oxidation reagent can be from about 0.05 mM to about 50 mM, more preferably about 0.1 mM to about 30 mM, and still more preferably about 0.2 mM to about 20 mM.
  • the total concentration of the redox reagent can be up to 35 mM, and can be in a range of 30 mM to 1 mM, or 25 mM to 5 mM or 15 mM to 5 mM.
  • the reduction/oxidation reagent can contain oxidized thiols at approximately higher, equal or lower concentrations as the reduced thiol component.
  • the reduction/oxidation reagent can be a combination of reduced glutathione and oxidized glutathione.
  • a ratio of reduced glutathione to oxidized glutathione of from about 1:1 to about 100:1 (reduced thiols:oxidized thiols) can function equally well.
  • the reduction/oxidation reagent can be cysteine or a combination of cysteine and cystine.
  • the ratio of reduced thiols to oxidized thiols can in a preferred embodiment be from about 1:10 to about 1000:1, more preferably about 1:1 to about 500:1, still more preferably about 5:1 to about 100:1, even more preferably about 10:1.
  • the redox reagent comprises a mix of cysteine/cystine.
  • the reduction/oxidation reagent can be from about 0.1 mM to about 30 mM cysteine and from about 0.05 mM to about 15 mM cystine.
  • the cysteine and cystine can be in a cysteinexystine ratio from about 1:50 to alternatively about 50:1.
  • the reduction/oxidation reagent comprises about 20 mM cysteine and about 1 mM cystine, i.e., a ratio or 20: 1.
  • the ratio of cysteine to cystine is from about 15:1, to 40:1. Even more specifically, the ratio of cysteine to cystine is 17:1. Even more specifically, the ratio of cysteine to cystine is 33 to 1. In one example, the latter ratio can be achieved where it contains 20 mM cysteine and 0.6 mM cystine. It is contemplated that 10 mM cysteine and 0.3 mM cystine may also be suitable to achieve the desired ratio.
  • the desired ratio of cysteine to cystine can be 50:1, 40:1, 33:1, 25:1, 20:1, 17:1, 12:1 or 10: 1 or even less depending on the reaction condition that best suits the Fc domain containing polypeptide.
  • the redox reagent comprises glutathione and the ratio of reduced glutathione to oxidized glutathione in the reduction/oxidation reagent can be from about 1 : 1 to about 100: 1.
  • the refolding can be performed using other redox reagents including copper.
  • chaperones and different buffer, temperature and time compositions can be used. The refolding step will thus triple the production of polypeptide, and reduce by three times the protein concentration need in formulation solutions to achieve the same activity.
  • the methods of the present invention may further comprise contacting the isolated polypeptide with a chaotropic agent.
  • the chaotropic agent is selected from the group consisting of urea, SDS and guanidine hydrochloride.
  • the chaotropic agent is guanidine hydrochloride.
  • the concentration of the guanidine hydrochloride may be varied according to particular conditions. IN certain specific embodiments, the concentration of guanidine hydrochloride can be from about 0.1 M to about 2 M. In particularly embodiments, the concentration of guanidine hydrochloride in the reaction mixture is from about 0.5 M to about 1.5 M. In still other exemplary embodiments, the concentration of guanidine hydrochloride in the reaction mixture is from about 0.8 M to about 1.2 M.
  • the methods of the invention contemplate the refolding on a column of a Fc domain containing polypeptide.
  • the polypeptide will be purified from expression systems on columns such as affinity resins such as A-1056 - 9 - concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®. It is also possible to utilize an affinity column comprising a polypeptide-binding polypeptide, such as a monoclonal antibody to the polypeptide, to affinity-purify expressed polypeptides.
  • affinity purification steps can be a Protein A, Protein G or Protein L column (e.g., MabSelect Sure®, ProSepvA® or ProSep vA Ultra®, Red-Oxi), which affinity agents bind to proteins that contain Fc domains.
  • the preparation of polypeptide is purified and treated according to the invention on a Protein A affinity column.
  • the polypeptides can be removed from an affinity column using conventional techniques, e.g., in a high salt elution buffer and then dialyzed into a lower salt buffer for use or by changing pH or other components depending on the affinity matrix utilized, or can be competitively removed using the naturally occurring substrate of the affinity moiety.
  • the methods of the invention result in a higher degree of purity of the treated polypeptide.
  • the redox and refold step on the column reduces the amount of free light chain in the mixture as it is washed out of the column after the treatment step.
  • the resulting antibody preparation is then more pure in that there is less contaminating species of proteins that are not a full length antibody, i.e., light chains, and also the antibody is more correctly folded.
  • the invention provides methods of increasing the recovery of active polypeptides.
  • the invention involves promoting a desired conformation of a protein in preparations of a polypeptide.
  • Using the methods of the invention on preparations of polypeptide results in a higher percentage, or higher relative fraction, of the polypeptide in the preparation with a desired conformation.
  • a desired conformation for a polypeptide is the three-dimensional structure of a protein that most closely resembles, and/or duplicates the function of, the naturally occurring domain of that protein.
  • the desired conformation of a polypeptide may have other tertiary structure characteristics.
  • a desired conformation may be a monomer, dimer, trimer, tetramer, or some other higher order form of the protein.
  • the "conformation" of a protein is its three- dimensional structure. Two different structures of a polypeptide with the same primary amino acid sequence are "conformers" of each other when they have different conformations corresponding to energy minima, and they differ from each other only in the way their atoms are oriented in space. Conformers can be interconverting (referring to the rotational freedom around bonds to the exclusion of breaking bonds).
  • configurational isomers Two different structures of a polypeptide with the same primary amino acid sequence are "configurational isomers" when they have different conformations corresponding to energy minima, they differ from each other in the way their atoms are oriented in space, and they are non- interconvertible without the breaking of a covalent bond.
  • configurational isomers can be interconverted by, for example, breaking and optionally reforming disulfide bonds.
  • the invention contemplates contacting a preparation of polypeptide that is made up of a heterogeneous mixture of least two configurational isomers of the polypeptide to a reduction/oxidation reagent for a time sufficient to increase the relative proportion of the desired configurational isomer and determining the relative proportion of the desired configurational isomer in the mixture.
  • the invention contemplates contacting a preparation of a polypeptide that has been produced by mammalian cells with a reduction/oxidation coupling reagent, at a pH of about 7 to about 11, and isolating a fraction of the preparation of the polypeptide with a desired conformation.
  • Polypeptides can be glycosylated polypeptides such as, e.g., those produced by eukaryotic cells.
  • the methods of the present invention are used to reduce the conformational heterogeneity that is induced by disulphide scrambling.
  • conformational heterogeneity is present in antibodies and A-1056 - 11 - more particularly, IgG2 antibodies.
  • configuration is used interchangeably with the term “conformation” herein throughout and is intended to mean a protein that has a different secondary, tertiary or quaternary structure from another protein that has the same primary structure (the same amino acid sequence).
  • redox reagents either alone or in combination with the further processing using chaotropic agents, it is possible to produce a more structurally homogeneous, and more therapeutically active polypeptide compared to a sample of the same protein produced in the same manner but for the presence of the redox reagents and/or chaotropes.
  • the methods of the invention find particular use in treating proteins that have at least about 3 cysteine residues.
  • proteins such as antibodies are high molecular weight moieties and the methods described herein are particularly useful for the production of uniform conformations of such high molecular weight proteins.
  • An antibody is understood to include polyclonal and monoclonal antibodies as well as humanized or chimeric forms.
  • An Fc domain containing polypeptide is understood to include those that include portions of an antibody Fc domain such that the fusion polypeptide can be purified on a column in a manner similar to an antibody.
  • a "domain” is a contiguous region of the polypeptide chain that adopts a particular tertiary structure and/or has a particular activity that can be localized in that region of the polypeptide chain.
  • one domain of a protein can have binding affinity for one ligand, and one domain of a protein can have binding affinity for another ligand.
  • a domain can refer to a cooperative unfolding unit of a protein.
  • Such proteins that contain more than one domain can be found naturally occurring as one protein or genetically engineered as a fusion protein.
  • domains of a polypeptide can have subdomains.
  • compositions and methods are useful for preparation of polypeptides, including immunoglobulin molecules or portions thereof, e.g., Fc A-1056 - 12 - fusion polypeptides, and chimeric antibodies (e.g., an antibody having a human constant region coupled to a murine antigen binding region) or fragments thereof produced from any desired expression system.
  • immunoglobulin molecules or portions thereof e.g., Fc A-1056 - 12 - fusion polypeptides
  • chimeric antibodies e.g., an antibody having a human constant region coupled to a murine antigen binding region
  • DNA encoding immunoglobulin molecules can be manipulated to yield DNAs capable of encoding polypeptides such as single chain antibodies, antibodies with enhanced affinity, or other antibody-based polypeptides in eukaryotic and prokaryotic expression systems (see, for example, Larrick et al., 1989, Biotechnology 7:934-938; Reichmann et al., 1988, Nature 332:323-327; Roberts et al., 1987, Nature 328:731-734; Verhoeyen et al., 1988, Science 239:1534-1536; Chaudhary et al., 1989, Nature 339:394-397).
  • Certain embodiments contemplate expression systems that are mammalian cell based such that the Fc domain containing polypeptides are modified in a manner most like natural human proteins.
  • Preparations of fully human antibodies (such as are prepared using transgenic animals, and optionally further modified in vitro), as well as humanized antibodies, can also be used in the invention.
  • humanized antibody also encompasses single chain antibodies. See, e.g., Cabilly el al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent No. 0,125,023 Bl; Boss et al., U.S. Pat. No. 4,816,397; Boss et al., European Patent No. 0,120,694 Bl; Neuberger, M. S. et al., WO 86/01533; Neuberger, M. S. etal., European Patent No. 0,194,276 Bl; Winter, U.S. Pat. No. 5,225,539; Winter, European Patent No.
  • the method of the invention may also be used during the preparation of conjugates comprising an antibody and a cytotoxic or luminescent substance.
  • Such substances include: maytansine derivatives (such as DMl); enterotoxins (such as a Staphylococcal enterotoxin); iodine isotopes (such as iodine-125); technium isotopes (such as Tc- 99m); cyanine fluorochromes (such as Cy5.5.18); and ribosome-inactivating proteins (such as bouganin, gelonin, or saporin-S6).
  • enterotoxins such as a Staphylococcal enterotoxin
  • iodine isotopes such as iodine-125
  • technium isotopes such as Tc- 99m
  • cyanine fluorochromes such as Cy5.5.18
  • ribosome-inactivating proteins such as bouganin, gelonin, or saporin-S6
  • an Fc domain containing polypeptide is a soluble form of the TNF receptor fused to an Fc domain (TNFR:Fc), however, it is A-1056 - 13 - to be understood that any polypeptide containing an Fc domain is suitable for use in the instant formulation.
  • a commercially available TNFR:Fc is known as etanercept (Enbrel®, Immunex Corporation), which is a dimeric fusion polypeptide consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgGl.
  • the Fc component of etanercept contains the constant heavy 2 (CH2) domain, the constant heavy 3 (CH3) domain and hinge region, but not the constant heavy 1 (CHl) domain of human IgGl . It is to be understood that an Fc domain can contain one or all of the domains described above.
  • An Fc domain fusion polypeptide substantially similar to one of the following polypeptides is suitable for use in the present invention: a flt3 ligand, a CD40 ligand, erythropoeitin, thrombopoeitin, calcitonin, Fas ligand, ligand for receptor activator of NF-kappa B (RANKL), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), thymic stroma-derived lyrnphopoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, mast cell growth factor, stem cell growth factor, epidermal growth factor, RANTES, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, interferons, nerve growth factors, glucagon, interleukins 1 through 18, colony stimulating factors, lymphotoxin- ⁇ , tumor necrosis factor (TNF),
  • Polypeptides suitable for use according to the invention also include recombinant fusion polypeptides comprising an Fc domain of an antibody plus a receptor for any of the above-mentioned polypeptides or polypeptides substantially similar to such receptors.
  • These receptors include: both forms of TNFR (referred to as p55 and p75), Interleukin-1 receptors (type 1 and 2), Interleukin-4 receptor, Interleukin-15 receptor, Interleukin-17 receptor, Interleukin-18 receptor, granulocyte-macrophage colony stimulating factor receptor, granulocyte colony stimulating factor receptor, receptors for oncostatin- M and leukemia inhibitory factor, receptor activator of NF-kappa B (RANK), A-1056 - 14 - receptors for TRAIL (TRAIL receptors 1, 2, 3, and 4), and receptors that comprise death domains, such as Fas or Apoptosis-Inducing Receptor (AIR).
  • TNFR referred to as p55 and
  • CD polypeptides suitable for use in the present invention include differentiation antigens (referred to as CD polypeptides) or their ligands or polypeptides substantially similar to either of these, which are fused to an Fc domain of an antibody.
  • CD polypeptides are disclosed in Leukocyte Typing VI (Proceedings of the VIth International Workshop and Conference, Kishimoto, Kikutani et al., eds., Kobe, Japan, 1996). Similar CD polypeptides are disclosed in subsequent workshops. Examples of such antigens include CD27, CD30, CD39, CD40, and ligands thereto (CD27 ligand, CD30 ligand, etc.).
  • CD antigens are members of the TNF receptor family, which also includes 41BB ligand and OX40.
  • the ligands are often members of the TNF family, as are 41BB ligand and OX40 ligand. Accordingly, members of the TNF and TNFR families can be formulated according to the present invention. Enzymatically active polypeptides or their ligands can also be used according to the invention.
  • Examples include recombinant fusion polypeptides comprising an Fc domain of an antibody fused to all or part of one of the following polypeptides or their ligands or a polypeptide substantially similar to one of these: metalloproteinase-disintegrin family members, various kinases, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, globins, an IL-2 antagonist, alpha- 1 antitrypsin, TNF-alpha Converting Enzyme, ligands for any of the above- mentioned enzymes, and numerous other enzymes and their ligands.
  • metalloproteinase-disintegrin family members various kinases, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, Factor VIII, Factor IX, apolip
  • compositions comprising antibodies, human antibodies, humanized antibodies, chimeric antibodies, i.e. antibodies having human constant antibody immunoglobulin domains coupled to one or more murine variable antibody immunoglobulin domain, and/or non-human antibodies, or fragments thereof. While the present examples relate to antibodies described in detail in published US application US2004/0097712 Al (U.S. Application No. 10/656,769, incorporated herein by A-1056 - 15 - reference in its entirety) one of skill in the art will readily be able to determine by routine experimentation what other Fc domain containing polypeptides will be suitable for use in the methods of the invention.
  • the methods of the invention can also be used for compounds comprising an Fc domain containing polypeptide conjugated to a cytotoxic or luminescent substance.
  • cytotoxic or luminescent substances include: maytansine derivatives (such as DMl); enterotoxins (such as a Staphylococcal enterotoxins); iodine isotopes (such as iodine- 125); technetium isotopes (such as Tc-99m); cyanine fluorochromes (such as Cy5.5.18); and ribosome-inactivating polypeptides (such as bouganin, gelonin, or saporin-S6).
  • enterotoxins such as a Staphylococcal enterotoxins
  • iodine isotopes such as iodine- 125
  • technetium isotopes such as Tc-99m
  • cyanine fluorochromes such as Cy5.5.18
  • ribosome-inactivating polypeptides such
  • polypeptide-substance conjugates contemplated for use in the invention include those that recognize one or more of the following antigens: CD2 5 CD3, CD4, CD8, CDl Ia, CD14, CDl 8, CD20, CD22, CD23, CD25, CD33, CD40, CD44, CD52, CD80 (B7.1), CD86 (B7.2), CD 147, IL-4, IL-5, IL-8, IL-IO 5 IL-2 receptor, IL-4 receptor, IL-6 receptor, IL- 13 receptor, PDGF- ⁇ , VEGF, TGF, TGF- ⁇ 2, TGF- ⁇ l, EGF receptor, VEGF receptor, C5 complement, IgE, tumor antigen CA125, tumor antigen MUCl, PEM antigen, LCG (which is a gene product that is expressed in association with lung cancer), HER-2, a tumor-associated glycoprotein TAG- 72, the SK-I antigen, tumor- associated epitopes that are present in elevated levels in the sera of patients with colon and/or
  • Respiratory Syncitial Virus Respiratory Syncitial Virus, human immunodeficiency virus (HIV), hepatitis B virus (HBV), Streptococcus mutans, and Staphylococcus aureus.
  • the methods of the invention can also be used for modifying the conformation of anti-idiotypic antibodies, or substantially similar polypeptides, including but not limited to anti-idiotypic antibodies against: an antibody targeted to the tumor antigen gp72; an antibody against the ganglioside GD3; or an antibody against the ganglioside GD2.
  • Fc domain fusion polypeptides include proteins expressed as a fusion with a portion of an immunoglobulin molecule, proteins expressed as fusion proteins with a zipper moiety, and novel polyfunctional proteins such as a fusion proteins of a cytokine and a growth factor (i.e., GM-CSF and IL-3, MGF and IL-3).
  • novel polyfunctional proteins such as a fusion proteins of a cytokine and a growth factor (i.e., GM-CSF and IL-3, MGF and IL-3).
  • WO 93/08207 and WO 96/40918 describe the preparation of various soluble oligomeric forms of a molecule referred to as CD40L, including an immunoglobulin fusion protein and a zipper fusion protein, respectively; the techniques discussed therein are applicable to other proteins.
  • any of the above molecules can be expressed as a fusion protein including but not limited to the extracellular domain of a cellular receptor molecule, an enzyme, a hormone, a cytokine, a portion of an immunoglobulin molecule, a zipper domain, and an epitope.
  • partially purified means that some fractionation procedure, or procedures, have been carried out, but that more polypeptide species (at least 10%) than the desired protein or protein conformation is present.
  • concentration ranges are 0.1 to 100 mg/ml, from 0.5 to 40 mg/ml, and from 1 to 10 mg/ml.
  • polypeptide can be prepared initially by culturing recombinant host cells under culture conditions suitable to express the polypeptide, in the presence of the redox reagents as described herein.
  • the polypeptide can also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are A-1056 - 17 - characterized by somatic or germ cells containing a nucleotide sequence encoding the polypeptide.
  • the resulting expressed polypeptide can then be purified, or partially purified, from such culture or component (e.g., from culture medium or cell extracts or bodily fluid) using known processes.
  • fractionation including but not limited to one or more steps of filtration, centrifugation, precipitation, phase separation, affinity purification, gel filtration, ion exchange chromatography, hydrophobic interaction chromatography (HIC; using such resins as phenyl ether, butyl ether, or propyl ether), HPLC, or some combination of above
  • HIC hydrophobic interaction chromatography
  • HPLC hydrophobic interaction chromatography
  • Some or all of the foregoing purification steps, in various combinations, can also be employed to prepare an appropriate preparation of a polypeptide for use in the methods of the invention, and/or to further purify the recombinant polypeptide after contacting the preparation of the polypeptide with a reduction/oxidation coupling reagent.
  • the polypeptide that is substantially free of other mammalian polypeptides is defined as an "isolated polypeptide".
  • isolated polypeptide The specific LC methods that may be combined with the redox reagent-based methods described herein are described in further detail below.
  • polypeptide can also be produced by known conventional chemical synthesis. Methods for constructing polypeptides by synthetic means are known to those skilled in the art. The synthetically-constructed polypeptide sequences can be glycosylated in vitro.
  • the desired degree of final purity depends on the intended use of the polypeptide.
  • a relatively high degree of purity is desired when the polypeptide is to be administered in vivo, for example.
  • the polypeptides are purified such that no polypeptide bands corresponding to other polypeptides are detectable upon analysis by SDS-polyacrylamide gel electrophoresis (SDS- A-1056 - 18 -
  • polypeptide of the invention is purified to substantial homogeneity, as indicated by a single polypeptide band upon analysis by SDS- PAGE.
  • the polypeptide band can be visualized by silver staining, Coomassie blue staining, and/or (if the polypeptide is radiolabeled) by autoradiography.
  • contacting is meant subjecting to, and/or exposing to, in solution.
  • the protein or polypeptide can be contacted with the redox reagents while also bound to a solid support (e.g., an affinity column or a chromatography matrix).
  • a solid support e.g., an affinity column or a chromatography matrix.
  • the pH of the solution is chosen to protect the stability of the protein and to be optimal for disulfide exchange.
  • the pH of the solution is preferably not strongly acidic.
  • preferred pH ranges are greater than pH 5, preferably about pH 6 to about pH 11 , more preferably from about pH 7 to about pH 10, and still more preferably from about pH 7.6 to about pH 9.6.
  • the optimal pH was found to be about pH 8.6.
  • the optimal pH for a particular embodiment of the invention can be easily determined experimentally by those skilled in the art.
  • the contacting may be performed by providing the redox reagent to the fermentation medium in which the protein is being generated. Alternatively, the A-1056 - 19 -
  • the contacting takes place upon partial purification of the protein from the cell culture in which it is generated. In still other embodiments, the contacting is performed after the protein has been eluted from the HPLC column but before any further processing. Essentially, the contacting may be performed at any stage during preparation, purification, storage or formulation of the antibody.
  • the contacting step can be performed for as short as about 1 hour to about 4 hours, and as long as about 6 hours to about 4 days. It has been found that a contacting step of about 4 to about 16 hours or about 18 hours works well.
  • the contacting step can also take place during another step, such as on a solid phase or during filtering or any other step in purification.
  • the methods of the invention can be performed over a wide temperature range.
  • the methods of the invention have been successfully carried out at temperatures from about 4°C to about 37°C, however the best results were achieved at lower temperatures.
  • a typical temperature for contacting a partially or fully purified preparation of the polypeptide is about 4°C to about 25°C (ambient), but can also be performed at lower temperatures and at higher temperature.
  • the preparation of polypeptide can be contacted with the reduction/oxidation reagent in various volumes as appropriate.
  • the methods of the invention have been carried out successfully at the analytical laboratory-scale (1-50 mL), preparative-scale (50 niL-10 L) and manufacturing- scale (10 L or more).
  • the methods of the invention can be carried out on both small and large scale with reproducibility.
  • the presently described reaction can be quenched in any way known to those of skill in the art.
  • the reduction/oxidation reagent can be removed and/or it can be chemically inactivated by, e.g., acidifying the solution.
  • the pH of the solution containing the reduction/oxidation reagent will be brought below pH 7, and generally the pH is reduced to between about pH 2 and about pH 7.
  • Determining the conformation of a protein, and the relative proportions of a conformation of a protein in a mixture can be done using any of a variety of analytical and/or qualitative techniques. For example, highly sensitive LC and LC/MS methods described in U.S. Patent Application No: 60/548,302, Dillon et al. filed February 27, 2004 and Dillon et al., Journal of Chromatography A, 1053 (2004) 299-305 and references cited therein can be used.
  • Determining the conformation can also be done by way of an activity assay (e.g., binding to a ligand, enzymatic activity, biological activity, etc.).
  • an activity assay e.g., binding to a ligand, enzymatic activity, biological activity, etc.
  • bioassays for polypeptide activity may be assessed using a chondrocyte activity assay by monitoring IL-6 and MMP 13 levels in the presence and absence of the refolded polypeptide.
  • the EC50 values in such assays may be determined using techniques known to those of skill in the art.
  • Isolating is meant physical separation of at least one component in a mixture away from other components in a mixture. Isolating components or particular conformations of a protein can be achieved using any purification method that tends to separate such components. Accordingly, one can perform multiple chromatography steps in addition to the RP-HPLC described above, including but not limited to HIC, hydroxyapatite chromatography, ion exchange chromatography, affinity, and SEC. Other purification methods are filtration (e.g., tangential flow filtration), electrophoretic techniques (e.g., electrophoresis, electroelution, isoelectric focusing), and phase separation (e.g., PEG-dextran phase separation), to name just a few.
  • the fraction of the preparation of polypeptide that contains the protein in the undesired conformation A-1056 - 21 - can be treated again in the methods of the invention, to further optimize the yields of protein with the desired conformation.
  • Analytical methods particularly suited for serving the purpose of the initial separation step include size-exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography, isoelectric focusing and capillary electrophoresis.
  • Ion-exchange chromatography relies on the affinity of a substance for the exchanger, which affinity depends on both the electrical properties of the material and the relative affinity of other charged substances in the solvent. Hence, bound material can be eluted by changing the pH, thus altering the charge of the material, or by adding competing materials, of which salts are but one example.
  • a size exclusion column otherwise known as gel filtration or gel permeation chromatography, relies on the penetration of macromolecules in a mobile phase into the pores of stationary phase particles. Differential penetration of the macromolecules is a function of the hydrodynamic volume of the particles. Size exclusion media exclude larger molecules from the interior of the particles while the smaller molecules are accessible to this volume. The order of elution can be predicted by the size of the protein as a linear relationship exists between elution volume and the log of the molecular weight of the protein being eluted.
  • hydrophobic interaction chromatography Certain proteins are retained on affinity columns containing hydrophobic spacer arms. This observation is exploited in the technique of hydrophobic interaction chromatography (HIC). Hydrophobic adsorbents now available include octyl or _, phenyl groups. Hydrophobic interactions are strong at high solution ionic strength, as such samples being analyzed need not be desalted before application to the adsorbent. Elution is achieved by changing the pH or ionic strength or by modifying the dielectric constant of the eluant using, for instance, ethanediol. A further detailed description of the general principles of hydrophobic interaction chromatography media may be found in U.S. Patent No. 3,917,527 and in U.S. A-1056 - 22 -
  • Patent No. 4,000,098 The application of HIC to the purification of specific proteins is exemplified by reference to the following disclosures: human growth hormone (U.S. Patent No. 4,332,717), toxin conjugates (U.S. Patent No. 4,771,128), antihemolytic factor (U.S. Patent No. 4,743,680), tumor necrosis factor (U.S. Patent No. 4,894,439), interleukin-2 (U.S. Patent No. 4,908,434), human lymphotoxin (U.S. Patent No. 4,920,196) and lysozyme species (Fausnaugh, J. L. and F. E. Regnier, J. Chromatog.
  • Suitable hydrophobic interaction chromatography media include, Pharmacia's phenyl-Sepharose, and Tosohaas' butyl, phenyl and ether Toyopearl 650 series resins.
  • affinity chromatography is another chromatographic technique that may be used herein.
  • affinity chromatography examples include immobilized metal affinity chromatography (IMAC), sulfated affinity chromatography, dye affinity chromatography, and heparin affinity.
  • the chromatographic medium may be prepared using one member of a binding pair, e.g., a. receptor/ligand binding pair, or antibody/antigen binding pair (irnmunoaffinity chromatography), hi certain embodiments, affinity chromatography is used to selectively separate IgG antibodies from a mixture of proteins by using protein A or G as a functionality of the stationary phase.
  • the methods of the invention can be used to prepare a protein formulation for use in a patient where the preparation involves mammalian cell production of the protein, purification of the protein from that mammalian cell culture, refolding of the purified protein using the refolding methods described herein, exchanging the buffer of the composition thus produced to formulation buffer and producing a single dose formulation that may be used in the patient.
  • the preparation of formulation involves the steps of mammalian cell production of the protein, purification of the protein followed by refolding of the protein as described herein, followed by isolation of desired form of the protein, after which the buffer of the composition thus A-1056 - 23 - produced is exchanged to formulation buffer and producing a single dose formulation that may be used in the patient.
  • the invention also optionally encompasses further formulating the proteins.
  • formulating is meant that the proteins can be buffer exchanged, sterilized, bulk-packaged and/or packaged for a final user.
  • sterile bulk form means that a formulation is free, or essentially free, of microbial contamination (to such an extent as is acceptable for food and/or drug purposes), and is of defined composition and concentration.
  • sterile unit dose form means a form that is appropriate for the customer and/or patient administration or consumption.
  • Such compositions can comprise an effective amount of the protein, in combination with other components such as a physiologically acceptable diluent, carrier, and/or excipient.
  • compositions suitable for administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
  • sterile bulk forms and sterile unit forms may contain a small concentration (approximately 1 microM to approximately 10 mM) of a reduction/oxidation reagent (e.g., glutathione, cysteine, etc.).
  • a reduction/oxidation reagent e.g., glutathione, cysteine, etc.
  • the polypeptides can be formulated according to known methods used to prepare pharmaceutically useful compositions.
  • Suitable formulations for pharmaceutical compositions include those described in Remington's Pharmaceutical Sciences, 16th ed. 1980, Mack Publishing Company, Easton, Pa.
  • compositions can be complexed with polyethylene glycol (PEG), metal ions, and/or incorporated into polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc., or incorporated into liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts.
  • PEG polyethylene glycol
  • metal ions and/or incorporated into polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc.
  • liposomes such as polyacetic acid, polyglycolic acid, hydrogels, dextran, etc.
  • Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like.
  • Sustained-release forms suitable for use include, but are not limited to, polypeptides that are encapsulated in a slowly-dissolving biocompatible polymer (such as the alginate microparticles described in U.S. Pat. No. 6,036,978), admixed with such a polymer (including topically applied hydrogels), and or encased in a biocompatible semi-permeable implant.
  • a slowly-dissolving biocompatible polymer such as the alginate microparticles described in U.S. Pat. No. 6,036,978
  • admixed with such a polymer including topically applied hydrogels
  • a human antibody to interleukin 1 receptor has been developed. This antibody is described in detail in US application US2004/0097712 Al (U.S. Application No. 10/656,769, incorporated herein) and is an IgG2 isotype. When this antibody was produced and purified using convention column chromatography methods, it had an elution profile using the HPLC/MS analysis of Dillon et al., Application No. 11/040,659, of three peaks.
  • Room temp (approximately 15 - 25 0 C)
  • refolding method 7 and 8 have the best profiles showing that the ratio of redox can be manipulated to improve antibody refolding on an affinity column.
  • FIG. 2 shows the comparison of experimental results from affinity column refolding versus solution refolding.
  • M588 is the result of refolding in solution
  • M589 is the same antibody refolded on an affinity column.
  • the methods may readily be adapted and used for any polypeptide that undergoes post-translational refolding and exhibits heterogeneity due to presence of disulfide bond that are A-1056 - 27 - amenable to scrambling, varying glycosylation patterns and the like while on a column.
  • the methods described herein may be especially useful for the production of other Fc domain containing polypeptides, and particularly IgGs such as for example, IgGl, IgG3 and IgG4 antibodies which may exhibit heterogeneity.
  • compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of certain or specific embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. AU such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
EP05851250A 2004-10-22 2005-10-24 Verfahren zur rückfaltung von polypeptiden Withdrawn EP1805205A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62129504P 2004-10-22 2004-10-22
US70176205P 2005-07-22 2005-07-22
US11/255,528 US7928205B2 (en) 2004-10-22 2005-10-21 Methods for refolding of recombinant antibodies
PCT/US2005/038045 WO2006047340A2 (en) 2004-10-22 2005-10-21 Methods for refolding of recombinant antibodies
PCT/US2005/038404 WO2006060083A1 (en) 2004-10-22 2005-10-24 Methods for refolding polypeptides

Publications (1)

Publication Number Publication Date
EP1805205A1 true EP1805205A1 (de) 2007-07-11

Family

ID=36565352

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05851250A Withdrawn EP1805205A1 (de) 2004-10-22 2005-10-24 Verfahren zur rückfaltung von polypeptiden

Country Status (4)

Country Link
EP (1) EP1805205A1 (de)
AU (1) AU2005310305A1 (de)
CA (1) CA2584137A1 (de)
WO (1) WO2006060083A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
DK2483289T4 (da) 2009-10-02 2025-05-19 Biogen Ma Inc Fremgangsmåder til forebyggelse og fjernelse af trisulfidbindinger
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
KR102537099B1 (ko) * 2014-12-22 2023-05-25 유씨비 바이오파마 에스알엘 단백질 제조 방법
EP3241022B1 (de) * 2014-12-31 2023-11-08 DH Technologies Development Pte. Ltd. Verfahren zur protein- und peptidreduktion
WO2018208743A1 (en) * 2017-05-09 2018-11-15 Bristol-Myers Squibb Company Method of controlling the formation of pink color during antibody manufacturing
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
AU2019246983B2 (en) 2018-04-02 2025-12-18 Amgen Inc. Erenumab compositions and uses thereof
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9225453D0 (en) * 1992-12-04 1993-01-27 Medical Res Council Binding proteins
CA2155335C (en) * 1993-02-04 2001-06-05 HANS CHRISTIAN THõGERSEN Improved method for the refolding of proteins
JP2005505494A (ja) * 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006060083A1 *

Also Published As

Publication number Publication date
WO2006060083A1 (en) 2006-06-08
AU2005310305A1 (en) 2006-06-08
CA2584137A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
AU2002255600B2 (en) Efficient recovery of correctly refolded proteins
EP1687328B1 (de) Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
JP4363986B2 (ja) タンパク質の精製方法
EP1805320B1 (de) Verfahren zur rückfaltung rekombinanter antikörper
US8263750B2 (en) Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
US20080167450A1 (en) Methods of purifying proteins
US10023608B1 (en) Protein purification methods to remove impurities
AU2002255600A1 (en) Efficient recovery of correctly refolded proteins
US8273707B2 (en) Process for purifying proteins
WO2006060083A1 (en) Methods for refolding polypeptides
AU2015371341B2 (en) Method of protein manufacture
HK1059267B (en) Efficient recovery of correctly refolded proteins
HK1176946B (en) Method for purifying immunoglobulin solutions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20070823

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081114